Takeda stock shifts to launches as FX lifts FY2026 outlook

Takeda's first-half results are putting commercial execution at the center of its next growth phase. In its October 29 release, the Japanese pharmaceutical group said revenue for the six months ended September 30, 2026, increased 8.4 percent at actual exchange rates but declined 1.0 percent at constant exchange rates.

New medicines shape the outlook

Takeda said ORZEYFUL was approved in the United States, Japan and China for narcolepsy type 1 and became available in Japan and China on October 15. Its U.S. launch remains subject to Drug Enforcement Administration scheduling. MIMRYLO launched in the United States in August for adults with polycythemia vera.

The company also said the U.S. Food and Drug Administration accepted zasocitinib for Priority Review, while the European Medicines Agency is reviewing the application. Zasocitinib remains investigational and requires regulatory approval before commercialization.

Currency benefit lifts guidance

Takeda raised its FY2026 revenue forecast to 4.7 trillion yen from 4.64 trillion yen and lifted core operating profit guidance to 1.19 trillion yen from 1.16 trillion yen. Adjusted free cash flow guidance increased to a range of 700.0 billion yen to 800.0 billion yen from 650.0 billion yen to 750.0 billion yen. Management said the revisions mainly reflect foreign-exchange benefits, while the constant-exchange-rate revenue outlook remains a low-single-digit decline.

First-half reported operating profit rose 60.4 percent, helped by the end of amortization for VYVANSE intangible assets and lower impairment charges. Adjusted free cash flow was 325.7 billion yen, down from 525.4 billion yen in the prior-year period. The distinction between reported gains and constant-currency trends remains important as investors assess launch execution and pressure from mature products.

December strategy update ahead

Takeda will hold a Capital Markets Day in Tokyo on December 11, 2026. Investors are likely to focus on the rollout of ORZEYFUL and MIMRYLO, the regulatory path for zasocitinib, transformation savings and the pipeline beyond Horizon One.

Japan's Nikkei 225 provides the broader market setting for Takeda's home market.

More news and analyses on Takeda stock will follow product launches, regulatory milestones and the company's longer-term strategy.